Skip to main content

Month: April 2025

DeFi Development Corporation Adds $9.9M in Solana to Treasury

BOCA RATON, FL, April 23, 2025 (GLOBE NEWSWIRE) — DeFi Development Corporation (Nasdaq: JNVR) (the “Company”) today announced the purchase of approximately 65,305 Solana (SOL) tokens. Following this transaction, DeFi Development Corporation now holds approximately 317,273 SOL, valued at $48.2 million, including staking rewards. Below is a summary of DeFi Development Corporation’s current SOL position and key per-share metrics as of April 23, 2025:Total SOL Held: 317,273 $ Value of SOL Held: approximately $48.2 million Total Shares Outstanding: Approximately 1.5M SOL per Share (“SPS”): 0.22, valued at $32.88 per share SOL/Share Growth (“SPS” Growth vs. last purchase): 40%A portion of the Solana acquired includes locked SOL sourced via BitGo’s OTC desk, which facilitates purchases from institutional sellers subject to time-based...

Continue reading

Former U.S. Customs Chief Endorses CustomsTrace AI™ as Critical to National and Economic Security

ScanTech AI’s New Platform is Being Designed to Address Critical Vulnerabilities in National Security Infrastructure Atlanta, GA, April 23, 2025 (GLOBE NEWSWIRE) — ScanTech AI Systems Inc. (the “Company” or “ScanTech AI”) (Nasdaq: STAI),  a global innovator in non-intrusive, fixed-gantry CT (Computed Tomography) screening technologies, announced that the development of its groundbreaking CustomsTrace AI™ platform has been endorsed by former U.S. Customs and Border Protection Commissioner Ralph Basham as critical to both national and economic security. Basham, who also previously served as Director of the U.S. Secret Service, stated, “As the former Commissioner of U.S. Customs and Border Protection, I can attest that this technology could be a vital tool in safeguarding our nation from a wide...

Continue reading

SBM Offshore starts EUR141 million share repurchase following successful completion of the 2024 program

Amsterdam, April 23, 2025 SBM Offshore announces the completion of its EUR130 million share repurchase program initiated in 2024, and the commencement of a EUR141 million (US$150 million equivalent1) share repurchase program, as announced on February 20, 2025 and effective from April 24, 2025.  EUR141 million share repurchase program The objective of the EUR141 million share repurchase program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs (maximum US$25 million). The remainder of the repurchased shares will be cancelled. The share repurchase program is expected to be completed by February 26, 2026 and will be executed under the authorization granted by the Annual General Meeting of the Company on April 9, 2025. The share repurchase program will be executed under the terms...

Continue reading

XA Investments Finds Strong Start to 2025 in Fund Launches and Asset Gathering Among Non-Listed Closed End Funds in its First Quarter 2025 Market Update

CHICAGO, April 23, 2025 (GLOBE NEWSWIRE) — XA Investments LLC (“XAI”), an alternative investment management and consulting firm, announced today that its Non-Listed Closed-End Funds First Quarter 2025 Market Update shows a strong start to 2025 in both fund launches and asset gathering. The market update is a comprehensive research report detailing current market trends and industry highlights. The non-listed closed-end fund (CEF) market includes all interval and tender offer funds. The report introduces the XAI Interval Fund Index™ (INTVL), analyzes recent developments in co-investment relief, and reviews 2024 net flows across the market. “The non-listed CEF market continues to grow after a record year in 2024, with many sponsors launching a second fund and new sponsors entering the market” stated Kimberly Flynn, the president...

Continue reading

Lottery.com in Final Stages of 2-Year Turnaround

Company Launches Aggressive $250 Million Growth Strategy FORT WORTH, Texas, April 23, 2025 (GLOBE NEWSWIRE) — Lottery.com Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or the “Company”) today provides an update on its two-year transformation, marking a new era of financial strength, operational momentum, and strategic expansion. Backed by $250 million in committed funding, fully Nasdaq-compliant, and generating strong market engagement, the Company now embarks on an aggressive buy-and-build strategy aimed at positioning the Company for success in both domestic and international markets. The April 2025 Annual General Meeting and Investors Lunch at Mar-a-Lago celebrated the close of Lottery.com’s financial restructuring. Key Achievements:$150 Million Commitment from United Capital Investments London (UCIL) –...

Continue reading

Andes Technology and Imagination Technologies Showcase Android 15 on High-Performance RISC-V Based Platform

SANTA CLARA, CA , April 23, 2025 (GLOBE NEWSWIRE) — Andes Technology (TWSE: 6533; SIN: US03420C2089; ISIN: US03420C1099), the leading supplier of high-efficiency, low-power 32/64-bit RISC-V processor cores and Founding Premier member of RISC-V International, in collaboration with Imagination Technologies, today announces the successful demonstration of Android 15 (Vanilla Ice Cream) running on a high-performance RISC-V-based hardware system. This achievement highlights the growing potential of RISC-V as a platform for rich operating systems and advanced graphical applications. The demonstration leverages Andes’ Voyager Board, powered by its Qilai SoC, in combination with Imagination’s GPU integrated within a graphics card. Together, the companies are showcasing a highly capable, fully operational Android system built on open hardware...

Continue reading

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science SA (Euronext – FR0010557264 – AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML). AB8939 had already obtained orphan drug designation from the US Food and Drug Administration (FDA) in AML. Granting of this orphan drug status in the EU is a significant milestone because it means that the COMP considered that AB8939 offers a significant benefit to people suffering from this condition in addition to existing treatments. Indeed, the criteria to obtain orphan drug designation at EMA differ...

Continue reading

UPDATE — HP Announces 2025 Digital Equity Accelerator Cohort

Selected nonprofit organizations are accelerating digital equity and powering the future of work in Greece, Indonesia, Nigeria, and Spain for disconnected communities News Highlights:Eight nonprofit organizations in Greece, Indonesia, Nigeria, and Spain selected for the 2025 Digital Equity Accelerator. Organizations are serving disconnected adolescents and adults through digital skills training, education access, and other community-driven initiatives. Each nonprofit will receive $100,000 of HP technology and solutions, capacity-building cash grants, and six–months of training and programming to support scale. In its first three years, the Accelerator helped 27 participating organizations expand their reach by more than 9 million people. The Digital Equity Accelerator, a joint initiative of HP Inc. and the HP Foundation, helps power...

Continue reading

Synergie : Revenues 1st Quarter 2025

Q1 2025 REVENUES In a complex economic environment, SYNERGIE generated sales of €757.5 million in the first quarter of 2025, up +0.8% in € m Q1 2025 Q1 2024 VariationInternational 463.7 447.9 +3.5%France 293.8 303.5 -3.2%Total 757.5 751.4 +0.8%SYNERGIE reported quarterly sales of €757.5 million, up +0.8% on previous year (-1.2% on a like-for-like basis). International business accounted for 61.2% of sales in the first quarter, compared to 59.6% in 2024. International sales grew by +3.5% in Q1 2025, driven by our acquisitions, which generated €14.3 million, and by an organic growth of +0.1%. Due to international political uncertainties and the economic difficulties faced by companies the downturn in certain markets in Northern and Eastern Europe weighed on this region’s performance (-2.8% on a like-for-like basis)....

Continue reading

UPDATE: Filevine Acquires Parrot, Expanding AI-Powered Legal Capabilities and Deposition Services

Acquisition Combines Industry-Leading Legal Workflows with Advanced AI Transcripts, Medical Record Summarization, and Remote Deposition ToolsFilevine Acquires ParrotFilevine extends its footprint into remote deposition services, transcript automation, and medical record management—three of the most time-consuming and costly areas in litigation.SALT LAKE CITY, UT, April 23, 2025 (GLOBE NEWSWIRE) — Filevine, the leading legal work platform trusted by over 150,000 legal professionals, today announced the acquisition of Parrot, the full-stack platform for transcribing, scheduling, and managing depositions. This marks Filevine’s third strategic acquisition, reinforcing its mission to deliver a “single pane of glass” where legal professionals can manage, track, and complete every aspect of their cases. “This acquisition is...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.